Jeff Boyd Novartis

Jeff has been with Novartis Pharmaceutical since December 2013. He was initially tasked to finalize the integration of the facility following the Dendreon acquisition and prepare for clinical and eventual commercial manufacturing for the Cell & Gene Therapies portfolio of products to include CTL019. He also leads the global technical operations function for the Cell & Gene Therapies unit responsible for all operational assets globally. Prior to joining Novartis, Jeff worked at Lonza for 15 years in various operational and functional roles with his last assignment leading global operational support for the Pharma segment. This included oversight of cell therapy custom manufacturing project management and operational excellence functions.